

### เอกสารอ้างอิง: อันตรกิริยาของโสมและยาแผนปัจจุบัน\_36(4)

1. วิทยา บุญวรพัฒน์. สารานุกรมสมุนไพรไทย-จีนที่ใช้บ่อยในประเทศไทย. กรุงเทพฯ: โรงพิมพ์ ส. พิจิตร การพิมพ์ จำกัด;2554.
2. สุรพจน์ วงศ์ใหญ่. ผลทางเภสัชวิทยาของสารจีนเซินโนไซด์ในโสมอเมริกาต่อสุขภาพ. วารสารพยาบาล ทหารบก. 2555;13(3):90-5.
3. เพ็ญพรรณ เวชวิทยาคลัง. ฤทธิ์ด้านการอักเสบของโสม. วารสารไทยโภชนาการ. 2555;7:1-15.
4. Chang TK, Chen J, Benetton SA. *In vitro* effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. *Drug Metab Dispos.* 2002;30(4):378-84.
5. Wang Y, Ye X, Ma Z, Liang Q, Lu B, Tan H, et al. Induction of cytochrome P450 1A1 expression by ginsenoside Rg1 and Rb1 in HepG2 cells. *Eur J Pharmacol.* 2008;601 (1-3):73-8.
6. Hao M, Ba Q, Yin J, Li J, Zhao Y, Wang H. Deglycosylated ginsenosides are more potent inducers of CYP1A1, CYP1A2 and CYP3A4 expression in HepG2 cells than glycosylated ginsenosides. *Drug Metab Pharmacokinet.* 2011;26(2):201-5.
7. Seong SJ, Kang WY, Heo JK, Jo J, Choi WG, Liu KH, et al. A Comprehensive *In vivo* and *In vitro* assessment of the drug interaction potential of red ginseng. *Clin Ther.* 2018;40(8): 1322-37.
8. Hao M, Zhao Y, Chen P, Huang H, Liu H, Jiang H, et al. Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. *PLoS One.* 2008;3(7):e2697.
9. Henderson GL, Harkey MR, Gershwin ME, Hackman RM, Stern JS, Stresser DM. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. *Life Sci.* 1999;65(15):PL209-14.
10. Foster BC, Vandenhoeck S, Tang R, Budzinski JW, Krantis A, Li KY. Effect of several Chinese natural health products of human cytochrome P450 metabolism. *J Pharm Pharmaceut Sci.* 2002;5(2):185-9.
11. He N, Xie HG, Collins X, Edeki T, Yan Z. Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes. *Clin Exp Pharmacol Physiol.* 2006;33(9):813-5.
12. He N, Edeki T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. *Am J Ther.* 2004;11(3):206-12.
13. Liu Y, Ma H, Zhang JW, Deng MC, Yang L. Influence of ginsenoside Rh1 and F1 on human cytochrome p450 enzymes. *Planta Med.* 2006;72(2):126-31.
14. Etheridge AS, Black SR, Patel PR, So J, Mathews JM. An *in vitro* evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, *Ginkgo biloba*, grape seed, milk thistle, and ginseng extracts and their constituents. *Planta Med.* 2007;73(8): 731-41.

15. Li Y, Wang Q, Yao X, Li Y. Induction of CYP3A4 and MDR1 gene expression by baicalin, baicalein, chlorogenic acid, and ginsenoside Rf through constitutive androstane receptor- and pregnane X receptor-mediated pathways. *Eur J Pharmacol.* 2010;640(1-3):46-54.
16. Kim SJ, Choi S, Kim M, Park C, Kim GL, Lee SO, et al. Effect of Korean red ginseng extracts on drug-drug interactions. *J Ginseng Res.* 2018;42(3):370-8.
17. Mohamed MF, Tseng T, Frye RF. Inhibitory effects of commonly used herbal extracts on UGT1A1 enzyme activity. *Xenobiotica.* 2010;40(10):663-9.
18. He YJ, Fang ZZ, Ge GB, Jiang P, Jin HZ, Zhang WD, et al. The inhibitory effect of 20(S)-protopanaxatriol (ppt) towards UGT1A1 and UGT2B7. *Phytother Res.* 2013;27(4):628-32.
19. Fang ZZ, Cao YF, Hu CM, Hong M, Sun XY, Ge GB, et al. Structure-inhibition relationship of ginsenosides towards UDP-glucuronosyltransferases (UGTs). *Toxicol Appl Pharmacol.* 2013;267(2):149-54.
20. Kim D, Zheng YF, Min JS, Park JB, Bae SH, Yoon KD, et al. *In vitro* stereoselective inhibition of ginsenosides toward UDP-glucuronosyltransferase (UGT) isoforms. *Toxicol Lett.* 2016;259:1-10.
21. Choi CH, Kang G, Min YD. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. *Planta Med.* 2003;69(3):235-40.
22. Patel J, Buddha B, Dey S, Pal D, Mitra AK. *In vitro* interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. *Am J Ther.* 2004; 11(4):262-77.
23. Li N, Wang D, Ge G, Wang X, Liu Y, Yang L. Ginsenoside metabolites inhibit P-glycoprotein *in vitro* and *in situ* using three absorption models. *Planta Med.* 2014;80(4):290-6.
24. Jiang R, Dong J, Li X, Du F, Jia W, Xu F, et al. Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3. *Br J Pharmacol.* 2015;172(4):1059-73.
25. Jin J, Shahi S, Kang HK, van Veen HW, Fan TP. Metabolites of ginsenosides as novel BCRP inhibitors. *Biochem Biophys Res Commun.* 2006;345(4):1308-14.
26. Zhu M, Chan KW, Ng LS, Chang Q, Chang S, Li RC. Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. *J Pharm Pharmacol.* 1999;51(2):175-80.
27. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. *Am J Health Syst Pharm.* 1997;54(6):692-3.
28. Rosado MF. Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product. *Cardiology.* 2003;99(2):111.
29. Lee SH, Ahn YM, Ahn SY, Doo HK, Lee BC. Interaction between warfarin and *Panax ginseng* in ischemic stroke patients. *J Altern Complement Med.* 2008;14(6):715-21.

30. Lee YH<sup>1</sup>, Lee BK, Choi YJ, Yoon IK, Chang BC, Gwak HS. Interaction between warfarin and Korean red ginseng in patients with cardiac valve replacement. *Int J Cardiol.* 2010;145(2):275-6.
31. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, et al. Effect of St. John's Wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. *Br J Clin Pharmacol.* 2004;57(5):592-9.
32. Ryu SH, Kim JW, Kim YS, Lee SH, Cho YB, Lee HK, et al. Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats. *J Toxicol Environ Health A.* 2014;77(22-24):1372-83.
33. Kim MG, Kim Y, Jeon JY, Kim DS. Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach. *Br J Clin Pharmacol.* 2016;82(6):1580-1590.
34. Zhang R, Jie J, Zhou Y, Cao Z, Li W. Long-term effects of *Panax ginseng* on disposition of fexofenadine in rats *in vivo*. *Am J Chin Med.* 2009;37(4):657-67.
35. Malati CY, Robertson SM, Hunt JD, Chairez C, Alfaro RM, Kovacs JA, et al. Influence of *Panax ginseng* on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants. *J Clin Pharmacol.* 2012;52(6):932-9.
36. Calderón MM, Chairez CL, Gordon LA, Alfaro RM, Kovacs JA, Penzak SR. Influence of *Panax ginseng* on the steady state pharmacokinetic profile of lopinavir-ritonavir in healthy volunteers. *Pharmacotherapy.* 2014;34(11):1151-8.